Literature DB >> 23572428

Statins and autoimmunity.

Saakshi Khattri1, Gisele Zandman-Goddard.   

Abstract

Statins have immunomodulatory effects. Hence, they could be advantageous for different reasons. First, statins can serve as adjunct therapy in autoimmune diseases. Second, they may play a role in the prevention of accelerated atherosclerosis in the same population. In this review, we discuss the mechanisms of immune regulation by statins and review the literature for their benefit in many autoimmune diseases. In these studies, statins lead to an improvement in the disease activity scores in rheumatoid arthritis patients; a reduction in prothrombotic factors in anti-phospholipid syndrome patients; changes in vasculature, proteinuria, and cardiac events in systemic lupus erythematosus patients; changes in vasculature and proteinuria in patients with vasculitis; disease activity scores in ankylosing spondylitis; and finally vascular changes in patients with systemic sclerosis. Hence, these studies suggest that statins could be used as adjuncts to standard therapy due to their anti-inflammatory, immunomodulatory, and anti-thrombogenic effects. More evidence-based research is required to determine whether statin regimens will become the standard of care in patients with autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572428     DOI: 10.1007/s12026-013-8409-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  69 in total

Review 1.  Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Authors:  John Greenwood; Lawrence Steinman; Scott S Zamvil
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.

Authors:  S Blankier; B W McCrindle; S Ito; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 4.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

5.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

6.  Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial.

Authors:  Chi Chiu Mok; Chun Kwok Wong; Chi Hung To; Judy Po Shan Lai; Cheuk Sum Lam
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

7.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

8.  Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Gordon H Guyatt; Deborah J Cook; Roman Jaeschke; Stephen G Pauker; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Statins as immunomodulators in systemic sclerosis.

Authors:  Anna Abou-Raya; Suzan Abou-Raya; Madihah Helmii
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

10.  Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.

Authors:  G A Ferreira; T P Navarro; R W Telles; L E C Andrade; E I Sato
Journal:  Rheumatology (Oxford)       Date:  2007-08-10       Impact factor: 7.580

View more
  20 in total

1.  Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity.

Authors:  Marit Westerterp; Emmanuel L Gautier; Anjali Ganda; Matthew M Molusky; Wei Wang; Panagiotis Fotakis; Nan Wang; Gwendalyn J Randolph; Vivette D D'Agati; Laurent Yvan-Charvet; Alan R Tall
Journal:  Cell Metab       Date:  2017-05-04       Impact factor: 27.287

2.  Effects of Topical Atorvastatin (2 %) on Posthemorrhoidectomy Pain and Wound Healing: A Randomized Double-Blind Placebo-Controlled Clinical Trial.

Authors:  Shahram Ala; Mina Alvandipour; Majid Saeedi; Maliheh Hamidian; Afshin Shiva; Nasrin Rahmani; Fatemeh Faramarzi
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

Review 3.  Neutrophil extracellular traps - the dark side of neutrophils.

Authors:  Ole E Sørensen; Niels Borregaard
Journal:  J Clin Invest       Date:  2016-05-02       Impact factor: 14.808

4.  Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis.

Authors:  Michelly Cristiny Pereira; Pablo Ramon Gualberto Cardoso; Laurindo Ferreira Da Rocha; Moacyr Jesus Barreto Melo Rêgo; Sayonara Maria Calado Gonçalves; Flaviana Alves Santos; Marina Rocha Galdino-Pitta; Andréa Tavares Dantas; Ângela Luzia Branco Pinto Duarte; Maira Galdino Da Rocha Pitta
Journal:  Inflamm Res       Date:  2014-01-14       Impact factor: 4.575

5.  Anti-inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials.

Authors:  Reem Faraj; Danyelle Paine; Stephen M Black; Ting Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease.

Authors:  Ryan Ungaro; Helena L Chang; Justin Côté-Daigneault; Saurabh Mehandru; Ashish Atreja; Jean-Frederic Colombel
Journal:  Am J Gastroenterol       Date:  2016-06-14       Impact factor: 10.864

7.  Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.

Authors:  S Colafrancesco; N Agmon-Levin; C Perricone; Y Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  KLF2 is a rate-limiting transcription factor that can be targeted to enhance regulatory T-cell production.

Authors:  Sudheer K Pabbisetty; Whitney Rabacal; Damian Maseda; Delphine Cendron; Patrick L Collins; Kristen L Hoek; Vrajesh V Parekh; Thomas M Aune; Eric Sebzda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

9.  Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database.

Authors:  Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-05-29       Impact factor: 3.535

10.  Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.

Authors:  Ning Zhao; Qian Dong; Cheng Qian; Sen Li; Qiong-Feng Wu; Dan Ding; Jing Li; Bin-Bin Wang; Ke-fang Guo; Jiang-jiao Xie; Xiang Cheng; Yu-Hua Liao; Yi-Mei Du
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.